The systemic amyloidoses are a group of complex diseases caused by tissue deposition of
misfolded proteins that results in progressive organ damage. The most common type …

Immunoglobulin light chain (AL) amyloidosis is the most common acquired systemic
amyloidoses. Its presentation is often insidious and progressive, which may delay diagnosis …

Immunoglobulin light-chain (AL) amyloidosis is a rare, incurable plasma cell disorder. Its
therapy has benefited immensely from the expanding drug armamentarium available for …

This first prospective phase 2 study of single-agent bortezomib in relapsed primary systemic
AL amyloidosis evaluated the recommended (maximum planned) doses identified in phase …

We evaluated the capability of soluble cardiac biomarkers to predict tolerability and
outcomes of IMiD‐containing treatments among 106 patients treated on clinical trials …

Abstract In this phase 1/2 study, we explored the feasibility and activity of an oral regimen of
lenalidomide with low-dose dexamethasone and low-dose oral cyclophosphamide (RdC) in …

The increasing number of effective agents allows rescue therapy of patients with light-chain
(AL) amyloidosis refractory to≥ 2 previous treatments. Lenalidomide is effective in this …

AL amyloidosis patients with multi‐organ and particularly cardiac involvement have
historically been considered to have a bad prognosis. The introduction of autologous stem …

The choice between ASCT and conventional-dose chemotherapy is based on accurate risk
assessment. Tight monitoring of hematologic and cardiac response is the cornerstone of …

Importance of the field: Treatment options for amyloidosis and polyneuropathy,
organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome have …